Thirty-two patients with scleroderma were treated with either sodium dextrothyroxine, 8 mg per day, or a placebo in an experimental double-blind study. No side effects were encountered. Judged on a clinical and laboratory basis, there was no difference between these two forms of therapy in their effect on scleroderma. It is suggested that objective evidence such as esophageal motility patterns provides the best basis for judgment as to the course of scleroderma.
WINKELMANN RK, KIERLAND RR, PERRY HO, MULLER SA. Treatment of Scleroderma With Sodium Dextrothyroxine: A Double-Blind Experimental Trial. Arch Dermatol. 1965;91(1):66–69. doi:10.1001/archderm.1965.01600070072012
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: